24.93USD-0.26%Mkt Cap: 285.50M USDP/E: —Last update: 2026-06-01
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target variou…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap285.50M USD
Enterprise Value204.18M USD
Revenue (TTM)7.49M USD
Gross Profit-24.64M USD
Net Income (TTM)-242.03M USD
Revenue/Share0.8050 USD
Last Price24.93 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.58
PEG—
EV/EBITDA-4.78
EV/Revenue27.25
P/S40.61
P/B-1.36
EPS (TTM)-36.59
EPS (Forward)-3.98
52W Range
7.60063% of range35.00
52W High35.00 USD
52W Low7.600 USD
Profitability
Gross Margin0.00%
Oper. Margin-209.12%
EBITDA Margin0.00%
Profit Margin-6960.77%
ROE128.90%
ROA-245.15%
Growth
Revenue Growth408.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.24M USD
CapEx (TTM)128.00K USD
FCF Margin-348.37%
FCF Yield-9.14%
Net Debt-100.13M USD
Net Debt/EBITDA2.35
Balance Sheet
Debt/Equity-0.04
Current Ratio11.91
Quick Ratio11.70
Book Value/Sh-19.2090 USD
Cash/Share9.208 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateDec 14, 2023
Analyst Consensus
Rating—
Target (Mean)42.50 USD
Target Range40.00 USD – 44.00 USD
# Analysts4
Ownership
Shares Out.11.61M
Float4.75M
Insiders3.18%
Institutions101.88%
Short Interest
Short Ratio4.9d
Short % Float8.56%
Short % Out.4.70%
Shares Short546.22K
Short (prev mo.)434.57K
Technical
SMA 5028.96 (-13.9%)
SMA 20020.51 (+21.6%)
Beta0.59
S&P 52W Chg27.70%
Avg Vol (30d)91.70K
Avg Vol (10d)100.16K
Technical Indicators
RSI (14)37.7
MACD-1.1655
MACD Signal-0.7148
MACD Hist.-0.4507
BB Upper34.44 USD
BB Middle28.85 USD
BB Lower23.26 USD
BB Width38.75%
ATR (14)2.118 USD
Vol Ratio (20d)1.41x